Methotrexate pharmacogenetics in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Brinker, R R ^a   Ranganathan, P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Methotrexate; Pharmacogenetics; Rheumatoid arthritis

Indexed keywords

ADENOSINE DEAMINASE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; AMINOIMIDAZOLE CARBOXAMIDE RIBONUCLEOTIDE; DEOXYURIDINE PHOSPHATE; DIHYDROFOLATE REDUCTASE; FOLIC ACID; GAMMA GLUTAMYL HYDROLASE; GENE PRODUCT; INOSINATE DEHYDROGENASE INHIBITOR; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; REDUCED FOLATE CARRIER; RIBONUCLEOTIDE; TETRAHYDROFOLIC ACID; THYMIDINE PHOSPHATE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; ABC TRANSPORTER; CHEMOKINE RECEPTOR CXCR6; GLYCINE HYDROXYMETHYLTRANSFERASE; TOLL LIKE RECEPTOR 4;

ARTICLE; CELL PROLIFERATION; DNA POLYMORPHISM; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TRANSPORT; DRUG UPTAKE; ENZYME ACTIVITY; GENE ACTIVITY; GENE FUNCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PURINE SYNTHESIS; PYRIMIDINE SYNTHESIS; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; DISEASE ACTIVITY SCORE; ENZYME METABOLISM; ENZYME SYNTHESIS; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HOMOZYGOSITY; MUCOSAL DISEASE; PNEUMONIA; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; SKIN DISEASE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; METHOTREXATE; PATIENT SELECTION; PHARMACOGENETICS; TREATMENT OUTCOME;

EID: 78650548876     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. EVANS WE, RELLING MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91. (Review).
2. EVANS WE, MCLEOD HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49.
3. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9. (see comment).
4. KREMER JM et al.: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15.
5. WEINBLATT ME et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. (see comment) (erratum appears in Arthritis Rheum 2003;48:855).
6. Arthritis Rheum 2003;48:35-45.
7. PRASHKER MJ, MEENAN RF: The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity. (see comment). Arthritis Rheum 1995;38:318-25.
8. BORST P, ELFERINK RO: Mammalian ABC transporters in health and disease. Ann Rev Biochem 2002;71:537-92.
9. HOOIJBERG JH, BROXTERMAN HI, KOOL M et al.: Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999;59:2532-5.
10. KOOL M, VAN DER LINDEN M, DE HAAS M et al.: MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999;96:6914-9.
11. GALIVAN J: Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol Pharmacol 1980;17:105-10.
12. SZETO DW, CHENG YC, ROSOWSKY A et al.: Human thymidylate synthetase-III. Effects of methotrexate and folate analogs. Biochem Pharmacol 1979;28:2633-7.
13. CHAN ES, CRONSTEIN BN: Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266-73.
14. CHANGO A, EMERY-FILLON N, DE COURCY GP et al.: A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. (see comment). Mol Genet Metab 2000;70:310-5.
15. WHETSTINE JR, GIFFORD AJ, WITT T et al.: Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His (27) and Arg (27) carriers. Clin Cancer Res 2001;7:3416-22.
16. DERVIEUX T, LEIN DO, PARK G et al.: Single nucleotide polymorphisms in the folate/purine synthesis pathway predict methotrexate's effects in rheumatoid arthritis (abstract). Arthritis Rheum 2003;48: S438.
17. CHAVE, KJ, RYAN TJ, CHMURA SE, GALIVAN J: Identification of single nucleotide polymorphisms in the human gamma-glutamyl hydrolase gene and characterization of promoter polymorphisms. Gene 2003;319:167-75.
18. DERVIEUX T, KREMER J, LEIN DO et al.: Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 2004;14:733-9.
19. CHENG Q, WU B, KAGER L et al.: A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics 2004;14:557-67.
20. HAYASHI H, FUJIMAKI C, DAIMON T et al.: Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis. J Clin Pharm Ther 2009;34:355-61.
21. VAN DER STRAATEN RJ, WESSELS JA, DE VRIES-BOUWSTRA JK et al.: Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics 2007;8:141-50.
22. NORRIS MD, DE GRAAF D, HABER M et al.: Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate, Int J Cancer 1996;65:613-9.
23. HOFFMEYER S, BURK O, VON RICHTER O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-8.
24. KIM RB, LEAKE BF, CHOO EF et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-99.
25. TANABE M, IEIRI I, NAGATA N et al.: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-43.
26. ULRICH CM, BIGLER J, VELICER CM et al.: Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 2000;9:1381-5.
27. TAKATORI R, TAKAHASHI KA, TOKUNAGA D et al.: ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol 2006, 24:546-54.
28. RANGANATHAN P, CULVERHOUSE R, MARSH S et al.: Methotrexate pathway gene polymorphisms and their effects on methotrexate toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008;35:550-2.
29. KOOLOOS WM, WESSELS JA, VAN DER STRAATEN T, ALLAART CF, HUIZINGA TW, GUCHELAAR HJ: Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics 2010;11:163-75.
30. KANG SS, ZHOU J, WONG PW, KOWALISYN J, STROKOSCH G: Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Gen 1988;43:414-21.
31. VAN DER PUT NM, GABREËLS F, STEVENS EM et al.: A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? (see comment). Am J Hum Genet 1998;62:1044-51. (Pubitemid 28199004)
32. WINEGRAD S, WEISBERG I: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity, (see comments). Circ Res 1998;83:60-72.
33. LECLERC D, CAMPEAU E, GOYETTE P et al.: Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996;5:1867-74.
34. CHEN J, STAMPFER MJ, MA J et al.: Influence of a methionine synthase (D919G) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction. Atherosclerosis 2001;154:667-72.
35. HARMON DL, SHIELDS DC, WOODSIDE JV et al.: Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol 1999;17:298-309.
36. WILSON A, PLATT R, WU Q et al.: A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab 1999;67:317-23.
37. GAUGHAN DJ, KLUIJTMANS LA, BARBAUX S et al.: The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 2001;157:451-6.
38. WESSELS JA, DE VRIES-BOUWSTRA JK, HEIJMANS BT et al.: Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 2006;54:1087-95.
39. FISHER MC, CRONSTEIN BN: Metaanalysis of methylenetetrahydrofolate reductase (MTH-FR) polymorphisms affecting methotrexate toxicity. J Rheumatol 2009;36:539-45.
40. HORIE N, AIBA H, OGURO K, HOJO H, TAKEISHI K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995, 20:191-7.
41. KAWAKAMI K, OMURA K, KANEHIRA E, WATANABE Y: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 1999;19:3249-52.
42. PULLARKAT ST, STOEHLMACHER J, GHADERI V et al.: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001;1:65-70.
43. Di PAOLO A, CHU E: The role of thymidylate synthase asamolecularbiomarker. (comment). Clin Cancer Res 2004, 10:411-2.
44. DERVIEUX T, FURST D, LEIN DO et al.: Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004;50:2766-74.
45. HEIL SG, VAN DER PUT NM, WAAS ET et al.: Is mutated serine hydroxymethyltransferase (SHMT) involved in the etiology of neural tube defects? Mol Genet Metab 2001;73:164-72.
46. WEISMAN MH, FURST DE, PARK GS et al.: Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 2006;54:607-12.
47. WESSELS JA, KOOLOOS WM, DE JONGE R et al.: Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recentonset rheumatoid arthritis. Arthritis Rheum 2006;54:2830-9.
48. HIDER SL, THOMSON W, MACK LF et al.: Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX. Rheumatology (Oxford) 2008;47:1156-9.
49. HUGHES LB, BEASLEY TM, PATEL H et al.: Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 2006;65:1213-8.